Shanghai-headquartered WuXi STA, a pharmaceutical development and manufacturing capability and technology platform company for the life sciences industry, is a subsidiary of WuXi AppTec.
The Couvet site is located in the canton of Neuchâtel, with commercial-scale production capacity for capsule and tablet dosage forms. The facility was designed to promote energy efficiency and environmental standards and can accommodate future growth.
The companies anticipate completing the transaction by Q2 2021, subject to regulatory approvals and the satisfaction of other closing conditions. Upon closing, WuXi STA will acquire the Couvet site’s operations and assets, which include the plant and equipment, as well as a workforce with technical capabilities and expertise.
“We are pleased to add the Couvet manufacturing facility to our growing global manufacturing site network and look forward to working with the talented team who share our focus on excellence and a patient-centered approach,” said Dr. Minzhang Chen, CEO of WuXi STA. “The acquisition will allow WuXi STA to better serve European markets and support our global customers to deliver innovative medicines and treatments to patients around the world.”
Lou Schmukler, Executive Vice President and President, Global Product Development and Supply, Bristol Myers Squibb, said: “This is an important step in the ongoing evolution of our manufacturing network to support our product portfolio. Switzerland remains an important strategic location for Bristol Myers Squibb, and we look forward to maintaining a strong presence in the Neuchâtel area.”